CTI BIOPHARMA CORP 4
4 · CTI BIOPHARMA CORP · Filed Mar 4, 2016
Insider Transaction Report
Form 4
Plunkett Matthew
EVP, Corporate Development
Transactions
- Sale
Common Stock
2016-03-04$0.59/sh−1,500$882→ 596,248 total - Sale
Common Stock
2016-03-04$0.59/sh−700$413→ 594,704 total - Sale
Common Stock
2016-03-04$0.59/sh−700$414→ 594,004 total - Sale
Common Stock
2016-03-04$0.59/sh−200$118→ 593,804 total - Sale
Common Stock
2016-03-04$0.59/sh−1,100$652→ 592,704 total - Sale
Common Stock
2016-03-04$0.59/sh−500$297→ 592,204 total - Sale
Common Stock
2016-03-04$0.59/sh−1,220$726→ 590,984 total - Sale
Common Stock
2016-03-04$0.60/sh−900$536→ 590,084 total - Sale
Common Stock
2016-03-04$0.58/sh−1,300$761→ 598,784 total - Sale
Common Stock
2016-03-04$0.59/sh−400$234→ 598,384 total - Sale
Common Stock
2016-03-04$0.59/sh−636$373→ 597,748 total - Sale
Common Stock
2016-03-04$0.59/sh−844$497→ 595,404 total
Footnotes (1)
- [F1]The sale was effected pursuant to a Rule 10b5-1 trading plan.